|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.461 USD | -3.96% |
|
-27.40% | -61.58% |
| Apr. 02 | Centogene Gets Nasdaq Noncompliance Notice | MT |
| Mar. 19 | Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics | MT |
Centogene N.V. reaffirmed earnings guidance for the year 2022. For the year, the company reaffirmed its previously communicated 2022 annual revenue guidance for year-over-year revenue growth of 15% to 20%. As a result, CENTOGENE expects revenues to be in the range of €50 million to €52 million.
This reflects the classification of the COVID-19 Testing Business as discontinued operations.
| 1st Jan change | Capi. | |
|---|---|---|
| -61.58% | 13.38M | |
| -1.82% | 41.36B | |
| +44.25% | 41.3B | |
| +2.56% | 39.61B | |
| -12.11% | 25.62B | |
| +3.09% | 24.09B | |
| -24.16% | 18.38B | |
| +22.12% | 11.85B | |
| -3.74% | 11.82B | |
| +7.75% | 11.07B |
CENTOGENE N.V. 
